Challenges When Expanding Transcatheter Aortic Valve Implantation to Younger Patients

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Challenges When Expanding Transcatheter Aortic Valve Implantation to Younger Patients. / De Backer, Ole; Søndergaard, Lars.

I: Frontiers in Cardiovascular Medicine, Bind 5, 45, 2018.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

De Backer, O & Søndergaard, L 2018, 'Challenges When Expanding Transcatheter Aortic Valve Implantation to Younger Patients', Frontiers in Cardiovascular Medicine, bind 5, 45. https://doi.org/10.3389/fcvm.2018.00045

APA

De Backer, O., & Søndergaard, L. (2018). Challenges When Expanding Transcatheter Aortic Valve Implantation to Younger Patients. Frontiers in Cardiovascular Medicine, 5, [45]. https://doi.org/10.3389/fcvm.2018.00045

Vancouver

De Backer O, Søndergaard L. Challenges When Expanding Transcatheter Aortic Valve Implantation to Younger Patients. Frontiers in Cardiovascular Medicine. 2018;5. 45. https://doi.org/10.3389/fcvm.2018.00045

Author

De Backer, Ole ; Søndergaard, Lars. / Challenges When Expanding Transcatheter Aortic Valve Implantation to Younger Patients. I: Frontiers in Cardiovascular Medicine. 2018 ; Bind 5.

Bibtex

@article{877432964dee486bbcbc5e1f91d8f248,
title = "Challenges When Expanding Transcatheter Aortic Valve Implantation to Younger Patients",
abstract = "The rapid expansion of transcatheter aortic valve implantation (TAVI) has been based upon robust clinical evidence derived from randomized controlled trials and large-scale international and national registries. Over the past decade, TAVI has evolved into a safe and effective procedure with predictable and reproducible outcomes. As a consequence, the TAVI technology is increasingly used to treat patients with a lower risk profile and the volume of TAVI now exceeds surgical aortic valve replacement (SAVR) in some countries. It may be anticipated that, in the near future, the majority of patients with severe symptomatic aortic valve stenosis will undergo TAVI as first line therapy, regardless of their age and risk profile. This article identifies some of the specific challenges that lie ahead when considering expansion of TAVI to younger patients.",
author = "{De Backer}, Ole and Lars S{\o}ndergaard",
year = "2018",
doi = "10.3389/fcvm.2018.00045",
language = "English",
volume = "5",
journal = "Frontiers in Cardiovascular Medicine",
issn = "2297-055X",
publisher = "Frontiers Media",

}

RIS

TY - JOUR

T1 - Challenges When Expanding Transcatheter Aortic Valve Implantation to Younger Patients

AU - De Backer, Ole

AU - Søndergaard, Lars

PY - 2018

Y1 - 2018

N2 - The rapid expansion of transcatheter aortic valve implantation (TAVI) has been based upon robust clinical evidence derived from randomized controlled trials and large-scale international and national registries. Over the past decade, TAVI has evolved into a safe and effective procedure with predictable and reproducible outcomes. As a consequence, the TAVI technology is increasingly used to treat patients with a lower risk profile and the volume of TAVI now exceeds surgical aortic valve replacement (SAVR) in some countries. It may be anticipated that, in the near future, the majority of patients with severe symptomatic aortic valve stenosis will undergo TAVI as first line therapy, regardless of their age and risk profile. This article identifies some of the specific challenges that lie ahead when considering expansion of TAVI to younger patients.

AB - The rapid expansion of transcatheter aortic valve implantation (TAVI) has been based upon robust clinical evidence derived from randomized controlled trials and large-scale international and national registries. Over the past decade, TAVI has evolved into a safe and effective procedure with predictable and reproducible outcomes. As a consequence, the TAVI technology is increasingly used to treat patients with a lower risk profile and the volume of TAVI now exceeds surgical aortic valve replacement (SAVR) in some countries. It may be anticipated that, in the near future, the majority of patients with severe symptomatic aortic valve stenosis will undergo TAVI as first line therapy, regardless of their age and risk profile. This article identifies some of the specific challenges that lie ahead when considering expansion of TAVI to younger patients.

U2 - 10.3389/fcvm.2018.00045

DO - 10.3389/fcvm.2018.00045

M3 - Journal article

C2 - 29868611

VL - 5

JO - Frontiers in Cardiovascular Medicine

JF - Frontiers in Cardiovascular Medicine

SN - 2297-055X

M1 - 45

ER -

ID: 218519382